Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
Abstract We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppress...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infectious Diseases 2021-12, Vol.8 (12), p.ofab559-ofab559 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | ofab559 |
|---|---|
| container_issue | 12 |
| container_start_page | ofab559 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 8 |
| creator | Pierre, Samuel Bocharova, Iryna Nguyen, Catherine Homeus, Fabienne Julmiste, Gaetane Macius, Youry Rouzier, Vanessa Severe, Patrice Marcelle Deschamps, Marie Moise, Colette Guiteau Bellot, Clovy Wu, Johnny Rivera, Vanessa R Sun, Rochelle Pape, Jean W Liautaud, Bernard Koenig, Serena P |
| description | Abstract
We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC. |
| doi_str_mv | 10.1093/ofid/ofab559 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8661077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A775975142</galeid><oup_id>10.1093/ofid/ofab559</oup_id><sourcerecordid>A775975142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-8a0b24661fb0a1872a62e75593d18a6f16b5902cb4ef63e1ca30e6de31bee2f93</originalsourceid><addsrcrecordid>eNp9UctuEzEUHSEQrUp3rJF3sGCKH_PcIEVRaZEidZEAEhvL47lOLpqxg-0Jyt_jUdKqbJAlv-455z5Olr1l9IbRVnxyBvu0qa4s2xfZJRe8yZu2rF8-u19k1yH8opQyRktat6-zC1G0lAkqLrPjetqDR-fJwxS1GyGQHxh3ZOlsRDuh3ZINWGfcAT35Dj5Mgaz_YNS7ORQd-Ym9O0w9WiBoyRq0s32-mp-LpOAh-pmqBrLZgVf744y6VxjxTfbKqCHA9fm8yr59ud0s7_PVw93X5WKV66KgMW8U7XhRVcx0VLGm5qriUKd2Rc8aVRlWdWVLue4KMJUAppWgUPUgWAfATSuuss8n3f3UjdBrsDGVI_ceR-WP0imU_0Ys7uTWHWSTktK6TgIfzgLe_Z4gRDli0DAMyoKbguQJlsbK2Zzr5gTdqgEkWuOSok6rhxHTZMBg-l_UddnWJSt4Inw8EbR3IXgwT3UxKmeH5eywPDuc4O-e9_IEfvQzAd6fAG7a_1_qL9SUs3s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610079219</pqid></control><display><type>article</type><title>Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pierre, Samuel ; Bocharova, Iryna ; Nguyen, Catherine ; Homeus, Fabienne ; Julmiste, Gaetane ; Macius, Youry ; Rouzier, Vanessa ; Severe, Patrice ; Marcelle Deschamps, Marie ; Moise, Colette Guiteau ; Bellot, Clovy ; Wu, Johnny ; Rivera, Vanessa R ; Sun, Rochelle ; Pape, Jean W ; Liautaud, Bernard ; Koenig, Serena P</creator><creatorcontrib>Pierre, Samuel ; Bocharova, Iryna ; Nguyen, Catherine ; Homeus, Fabienne ; Julmiste, Gaetane ; Macius, Youry ; Rouzier, Vanessa ; Severe, Patrice ; Marcelle Deschamps, Marie ; Moise, Colette Guiteau ; Bellot, Clovy ; Wu, Johnny ; Rivera, Vanessa R ; Sun, Rochelle ; Pape, Jean W ; Liautaud, Bernard ; Koenig, Serena P</creatorcontrib><description>Abstract
We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofab559</identifier><identifier>PMID: 34901303</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Anti-HIV agents ; Antiviral agents ; Brief Reports ; Care and treatment ; Darunavir ; DNA polymerases ; Highly active antiretroviral therapy ; HIV (Viruses) ; Proteases ; Reverse transcriptase inhibitors</subject><ispartof>Open Forum Infectious Diseases, 2021-12, Vol.8 (12), p.ofab559-ofab559</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><rights>COPYRIGHT 2021 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c440t-8a0b24661fb0a1872a62e75593d18a6f16b5902cb4ef63e1ca30e6de31bee2f93</cites><orcidid>0000-0001-8063-8773</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661077/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661077/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1604,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34901303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pierre, Samuel</creatorcontrib><creatorcontrib>Bocharova, Iryna</creatorcontrib><creatorcontrib>Nguyen, Catherine</creatorcontrib><creatorcontrib>Homeus, Fabienne</creatorcontrib><creatorcontrib>Julmiste, Gaetane</creatorcontrib><creatorcontrib>Macius, Youry</creatorcontrib><creatorcontrib>Rouzier, Vanessa</creatorcontrib><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Marcelle Deschamps, Marie</creatorcontrib><creatorcontrib>Moise, Colette Guiteau</creatorcontrib><creatorcontrib>Bellot, Clovy</creatorcontrib><creatorcontrib>Wu, Johnny</creatorcontrib><creatorcontrib>Rivera, Vanessa R</creatorcontrib><creatorcontrib>Sun, Rochelle</creatorcontrib><creatorcontrib>Pape, Jean W</creatorcontrib><creatorcontrib>Liautaud, Bernard</creatorcontrib><creatorcontrib>Koenig, Serena P</creatorcontrib><title>Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti</title><title>Open Forum Infectious Diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>Abstract
We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.</description><subject>Anti-HIV agents</subject><subject>Antiviral agents</subject><subject>Brief Reports</subject><subject>Care and treatment</subject><subject>Darunavir</subject><subject>DNA polymerases</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV (Viruses)</subject><subject>Proteases</subject><subject>Reverse transcriptase inhibitors</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9UctuEzEUHSEQrUp3rJF3sGCKH_PcIEVRaZEidZEAEhvL47lOLpqxg-0Jyt_jUdKqbJAlv-455z5Olr1l9IbRVnxyBvu0qa4s2xfZJRe8yZu2rF8-u19k1yH8opQyRktat6-zC1G0lAkqLrPjetqDR-fJwxS1GyGQHxh3ZOlsRDuh3ZINWGfcAT35Dj5Mgaz_YNS7ORQd-Ym9O0w9WiBoyRq0s32-mp-LpOAh-pmqBrLZgVf744y6VxjxTfbKqCHA9fm8yr59ud0s7_PVw93X5WKV66KgMW8U7XhRVcx0VLGm5qriUKd2Rc8aVRlWdWVLue4KMJUAppWgUPUgWAfATSuuss8n3f3UjdBrsDGVI_ceR-WP0imU_0Ys7uTWHWSTktK6TgIfzgLe_Z4gRDli0DAMyoKbguQJlsbK2Zzr5gTdqgEkWuOSok6rhxHTZMBg-l_UddnWJSt4Inw8EbR3IXgwT3UxKmeH5eywPDuc4O-e9_IEfvQzAd6fAG7a_1_qL9SUs3s</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Pierre, Samuel</creator><creator>Bocharova, Iryna</creator><creator>Nguyen, Catherine</creator><creator>Homeus, Fabienne</creator><creator>Julmiste, Gaetane</creator><creator>Macius, Youry</creator><creator>Rouzier, Vanessa</creator><creator>Severe, Patrice</creator><creator>Marcelle Deschamps, Marie</creator><creator>Moise, Colette Guiteau</creator><creator>Bellot, Clovy</creator><creator>Wu, Johnny</creator><creator>Rivera, Vanessa R</creator><creator>Sun, Rochelle</creator><creator>Pape, Jean W</creator><creator>Liautaud, Bernard</creator><creator>Koenig, Serena P</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8063-8773</orcidid></search><sort><creationdate>20211201</creationdate><title>Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti</title><author>Pierre, Samuel ; Bocharova, Iryna ; Nguyen, Catherine ; Homeus, Fabienne ; Julmiste, Gaetane ; Macius, Youry ; Rouzier, Vanessa ; Severe, Patrice ; Marcelle Deschamps, Marie ; Moise, Colette Guiteau ; Bellot, Clovy ; Wu, Johnny ; Rivera, Vanessa R ; Sun, Rochelle ; Pape, Jean W ; Liautaud, Bernard ; Koenig, Serena P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-8a0b24661fb0a1872a62e75593d18a6f16b5902cb4ef63e1ca30e6de31bee2f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-HIV agents</topic><topic>Antiviral agents</topic><topic>Brief Reports</topic><topic>Care and treatment</topic><topic>Darunavir</topic><topic>DNA polymerases</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV (Viruses)</topic><topic>Proteases</topic><topic>Reverse transcriptase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pierre, Samuel</creatorcontrib><creatorcontrib>Bocharova, Iryna</creatorcontrib><creatorcontrib>Nguyen, Catherine</creatorcontrib><creatorcontrib>Homeus, Fabienne</creatorcontrib><creatorcontrib>Julmiste, Gaetane</creatorcontrib><creatorcontrib>Macius, Youry</creatorcontrib><creatorcontrib>Rouzier, Vanessa</creatorcontrib><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Marcelle Deschamps, Marie</creatorcontrib><creatorcontrib>Moise, Colette Guiteau</creatorcontrib><creatorcontrib>Bellot, Clovy</creatorcontrib><creatorcontrib>Wu, Johnny</creatorcontrib><creatorcontrib>Rivera, Vanessa R</creatorcontrib><creatorcontrib>Sun, Rochelle</creatorcontrib><creatorcontrib>Pape, Jean W</creatorcontrib><creatorcontrib>Liautaud, Bernard</creatorcontrib><creatorcontrib>Koenig, Serena P</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open Forum Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pierre, Samuel</au><au>Bocharova, Iryna</au><au>Nguyen, Catherine</au><au>Homeus, Fabienne</au><au>Julmiste, Gaetane</au><au>Macius, Youry</au><au>Rouzier, Vanessa</au><au>Severe, Patrice</au><au>Marcelle Deschamps, Marie</au><au>Moise, Colette Guiteau</au><au>Bellot, Clovy</au><au>Wu, Johnny</au><au>Rivera, Vanessa R</au><au>Sun, Rochelle</au><au>Pape, Jean W</au><au>Liautaud, Bernard</au><au>Koenig, Serena P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti</atitle><jtitle>Open Forum Infectious Diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>8</volume><issue>12</issue><spage>ofab559</spage><epage>ofab559</epage><pages>ofab559-ofab559</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34901303</pmid><doi>10.1093/ofid/ofab559</doi><orcidid>https://orcid.org/0000-0001-8063-8773</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2328-8957 |
| ispartof | Open Forum Infectious Diseases, 2021-12, Vol.8 (12), p.ofab559-ofab559 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8661077 |
| source | DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Anti-HIV agents Antiviral agents Brief Reports Care and treatment Darunavir DNA polymerases Highly active antiretroviral therapy HIV (Viruses) Proteases Reverse transcriptase inhibitors |
| title | Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superior%20Outcomes%20With%20Continuing%20Tenofovir%20Versus%20Switching%20to%20Zidovudine%20in%20Second-Line%20Antiretroviral%20Therapy%20in%20Haiti&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.au=Pierre,%20Samuel&rft.date=2021-12-01&rft.volume=8&rft.issue=12&rft.spage=ofab559&rft.epage=ofab559&rft.pages=ofab559-ofab559&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofab559&rft_dat=%3Cgale_pubme%3EA775975142%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610079219&rft_id=info:pmid/34901303&rft_galeid=A775975142&rft_oup_id=10.1093/ofid/ofab559&rfr_iscdi=true |